CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth
Gilham, David E
Lee, S. P.
AffiliationInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham,
MetadataShow full item record
AbstractEngineering T cells to express chimeric antigen receptors (CARs) specific for antigens on hematological cancers has yielded remarkable clinical responses, but with solid tumors, benefit has been more limited. This may reflect lack of suitable target antigens, immune evasion mechanisms in malignant cells, and/or lack of T cell infiltration into tumors. An alternative approach, to circumvent these problems, is targeting the tumor vasculature rather than the malignant cells directly. CLEC14A is a glycoprotein selectively overexpressed on the vasculature of many solid human cancers and is, therefore, of considerable interest as a target antigen. Here, we generated CARs from 2 CLEC14A-specific antibodies and expressed them in T cells. In vitro studies demonstrated that, when exposed to their target antigen, these engineered T cells proliferate, release IFN-?, and mediate cytotoxicity. Infusing CAR engineered T cells into healthy mice showed no signs of toxicity, yet these T cells targeted tumor tissue and significantly inhibited tumor growth in 3 mouse models of cancer (Rip-Tag2, mPDAC, and Lewis lung carcinoma). Reduced tumor burden also correlated with significant loss of CLEC14A expression and reduced vascular density within malignant tissues. These data suggest the tumor vasculature can be safely and effectively targeted with CLEC14A-specific CAR T cells, offering a potent and widely applicable therapy for cancer.
CitationZhuang X, Maione F, Robinson J, Bentley M, Kaul B, Whitworth K, et al. CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth. JCI Insight. 2020;5(19).
- TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo.
- Authors: Petrovic K, Robinson J, Whitworth K, Jinks E, Shaaban A, Lee SP
- Issue date: 2019
- An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours.
- Authors: Robinson J, Whitworth K, Jinks E, Nagy Z, Bicknell R, Lee SP
- Issue date: 2020 Oct
- Effective Targeting of TAG72<sup>+</sup> Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.
- Authors: Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ
- Issue date: 2018
- Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
- Authors: Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW
- Issue date: 2018 Aug
- Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
- Authors: Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ
- Issue date: 2016